CD133: To be or not to be, is this the real question?

Elena Irollo, Giuseppe Pirozzi

Research output: Contribution to journalArticle

Abstract

CD133 (promini-1) is a member of the transmembrane glycoprotein family, was initially described as a specific marker to select human hematopoietic progenitor cells. Then, it was recognised as important marker to identify and isolate the specific cell subpopulation termed "cancer stem cells". Many studies showed that CD133+ cells have stemness properties such as self-renewal, differentiation ability, high proliferation and they are able also to form tumours in xenografts. Moreover it has been demonstrated that CD133+ cells more resistant to radiation and standard chemotherapy than CD133- cells. Although this, others investigations demonstrated that also CD133- cells can show the same characteristics of those positive for CD133+. Hence, some inconsistencies among published data on CD133 function can be ascribed to different causes questioning the main role as specific marker of cancer stem cells. In fact, many authors indicate that CD133 is expressed both in differentiated and undifferentiated cells, and CD133- cancer cells can also initiate tumours. Indeed, it is still a matter of debate whether CD133+ cells truly represent the ultimate tumourigenic population. However, the belief that CD133 may act as a universal marker of CSCs has been met with a high degree of controversy in the research community. In this review there is an attempt to highlight: i) the role and function of CD133, with an overview on the current stage of knowledge about this molecule, ii) the difficulty often encountered in its identification iii) the utility of CD133 expression as a prognostic marker.

Original languageEnglish
Pages (from-to)563-581
Number of pages19
JournalAmerican Journal of Translational Research
Volume5
Issue number6
Publication statusPublished - 2013

Fingerprint

Stem cells
Tumors
Chemotherapy
Heterografts
Glycoproteins
Cells
Radiation
Molecules
Neoplastic Stem Cells
Neoplasms
Hematopoietic Stem Cells
Drug Therapy
Research
Population

Keywords

  • Cancer stem cells
  • Circulating tumor cells
  • Epigenetic regulation
  • Epithelial-mesenchymal transition
  • Glycosylation
  • Prominin-1 (CD133)

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

CD133 : To be or not to be, is this the real question? / Irollo, Elena; Pirozzi, Giuseppe.

In: American Journal of Translational Research, Vol. 5, No. 6, 2013, p. 563-581.

Research output: Contribution to journalArticle

Irollo, Elena ; Pirozzi, Giuseppe. / CD133 : To be or not to be, is this the real question?. In: American Journal of Translational Research. 2013 ; Vol. 5, No. 6. pp. 563-581.
@article{c12e3b0c29ef4baca11e31be263e3b7a,
title = "CD133: To be or not to be, is this the real question?",
abstract = "CD133 (promini-1) is a member of the transmembrane glycoprotein family, was initially described as a specific marker to select human hematopoietic progenitor cells. Then, it was recognised as important marker to identify and isolate the specific cell subpopulation termed {"}cancer stem cells{"}. Many studies showed that CD133+ cells have stemness properties such as self-renewal, differentiation ability, high proliferation and they are able also to form tumours in xenografts. Moreover it has been demonstrated that CD133+ cells more resistant to radiation and standard chemotherapy than CD133- cells. Although this, others investigations demonstrated that also CD133- cells can show the same characteristics of those positive for CD133+. Hence, some inconsistencies among published data on CD133 function can be ascribed to different causes questioning the main role as specific marker of cancer stem cells. In fact, many authors indicate that CD133 is expressed both in differentiated and undifferentiated cells, and CD133- cancer cells can also initiate tumours. Indeed, it is still a matter of debate whether CD133+ cells truly represent the ultimate tumourigenic population. However, the belief that CD133 may act as a universal marker of CSCs has been met with a high degree of controversy in the research community. In this review there is an attempt to highlight: i) the role and function of CD133, with an overview on the current stage of knowledge about this molecule, ii) the difficulty often encountered in its identification iii) the utility of CD133 expression as a prognostic marker.",
keywords = "Cancer stem cells, Circulating tumor cells, Epigenetic regulation, Epithelial-mesenchymal transition, Glycosylation, Prominin-1 (CD133)",
author = "Elena Irollo and Giuseppe Pirozzi",
year = "2013",
language = "English",
volume = "5",
pages = "563--581",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "6",

}

TY - JOUR

T1 - CD133

T2 - To be or not to be, is this the real question?

AU - Irollo, Elena

AU - Pirozzi, Giuseppe

PY - 2013

Y1 - 2013

N2 - CD133 (promini-1) is a member of the transmembrane glycoprotein family, was initially described as a specific marker to select human hematopoietic progenitor cells. Then, it was recognised as important marker to identify and isolate the specific cell subpopulation termed "cancer stem cells". Many studies showed that CD133+ cells have stemness properties such as self-renewal, differentiation ability, high proliferation and they are able also to form tumours in xenografts. Moreover it has been demonstrated that CD133+ cells more resistant to radiation and standard chemotherapy than CD133- cells. Although this, others investigations demonstrated that also CD133- cells can show the same characteristics of those positive for CD133+. Hence, some inconsistencies among published data on CD133 function can be ascribed to different causes questioning the main role as specific marker of cancer stem cells. In fact, many authors indicate that CD133 is expressed both in differentiated and undifferentiated cells, and CD133- cancer cells can also initiate tumours. Indeed, it is still a matter of debate whether CD133+ cells truly represent the ultimate tumourigenic population. However, the belief that CD133 may act as a universal marker of CSCs has been met with a high degree of controversy in the research community. In this review there is an attempt to highlight: i) the role and function of CD133, with an overview on the current stage of knowledge about this molecule, ii) the difficulty often encountered in its identification iii) the utility of CD133 expression as a prognostic marker.

AB - CD133 (promini-1) is a member of the transmembrane glycoprotein family, was initially described as a specific marker to select human hematopoietic progenitor cells. Then, it was recognised as important marker to identify and isolate the specific cell subpopulation termed "cancer stem cells". Many studies showed that CD133+ cells have stemness properties such as self-renewal, differentiation ability, high proliferation and they are able also to form tumours in xenografts. Moreover it has been demonstrated that CD133+ cells more resistant to radiation and standard chemotherapy than CD133- cells. Although this, others investigations demonstrated that also CD133- cells can show the same characteristics of those positive for CD133+. Hence, some inconsistencies among published data on CD133 function can be ascribed to different causes questioning the main role as specific marker of cancer stem cells. In fact, many authors indicate that CD133 is expressed both in differentiated and undifferentiated cells, and CD133- cancer cells can also initiate tumours. Indeed, it is still a matter of debate whether CD133+ cells truly represent the ultimate tumourigenic population. However, the belief that CD133 may act as a universal marker of CSCs has been met with a high degree of controversy in the research community. In this review there is an attempt to highlight: i) the role and function of CD133, with an overview on the current stage of knowledge about this molecule, ii) the difficulty often encountered in its identification iii) the utility of CD133 expression as a prognostic marker.

KW - Cancer stem cells

KW - Circulating tumor cells

KW - Epigenetic regulation

KW - Epithelial-mesenchymal transition

KW - Glycosylation

KW - Prominin-1 (CD133)

UR - http://www.scopus.com/inward/record.url?scp=84885026715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885026715&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84885026715

VL - 5

SP - 563

EP - 581

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 6

ER -